Researchers involved in the Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients (SCOUT) trial have concluded that long-term use of the weight loss drug sibutramine (Meridia) was not associated with an increased risk of death; however, the drug was associated with a significantly increased risk of nonfatal myocardial infarctions and strokes among overweight and obese people with preexisting cardiovascular conditions. The findings were presented at the International Congress on Obesity in Stockholm, and then published in the September 1 issue of the New England Journal of Medicine. Read our story by Elizabeth Mechcatie here.
Mitchel Zoler spoke with Dr. Stephan Rössner of the obesity unit at the Karolinska Institute in Stockholm, who was an invited discussant for the SCOUT presentation. The drug is still a good option for patients without cardiovascular problems, he said. Sibutramine can be considered for patients with eating disorders, sleep apnea or arthritis, who need additional help losing or maintaining weight, provided that cardiovascular risk factors are monitored, he added.
Check back here or at Internal Medicine News next week, when Elizabeth Mechcatie will be covering the FDA Advisory Committee meeting on sibutramine September 15-16. You can follow Elizabeth’s coverage on Twitter, @ElizMech.